QIAGEN/$QGEN

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About QIAGEN

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Ticker

$QGEN

Primary listing

NYSE

Industry

Life Sciences Tools & Services
Headquarters

Employees

5,700

ISIN

NL0015002CX3

QIAGEN Metrics

BasicAdvanced
$11B
115.46
$0.42
0.68
$0.25
0.51%

Bulls say / Bears say

QIAGEN reported a 5% year-over-year increase in net sales for Q3 2024, with Diagnostic solutions leading at 10% constant exchange rate growth, indicating strong demand for its products. (globenewswire.com)
The company has set a target of 7% annual sales growth until 2028, focusing on lab testing machines for infections and cancer, suggesting a clear growth strategy. (reuters.com)
QIAGEN's adjusted operating income margin improved to 29.6% in Q3 2024, up 3 percentage points from the previous year, reflecting enhanced profitability. (globenewswire.com)
QIAGEN's net sales declined by 5% in Q1 2024 compared to the same period in 2023, indicating potential challenges in maintaining revenue growth. (biospace.com)
The company reported a net loss per share of $0.83 in Q2 2024, despite adjusted diluted EPS of $0.55, suggesting underlying financial pressures. (globenewswire.com)
QIAGEN's total assets decreased from $6.29 billion in 2022 to $5.69 billion in 2024, which may raise concerns about asset management and financial stability. (qiagen.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $QGEN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs